A promising personalized medicine initiative, but little funding

The National Institutes of Health is slated to receive $215 million with the hope of individualizing medical treatments by using patients genetic information.

In his State of the Union address on Jan. 20, President Barack Obama announced the Precision Medical Initiative, a program with the goal of enabling doctors to better understand diseases through genetic sequencing of patients and ultimately choose better treatments. In cancer treatment, for example, a patients tumor might be sequenced to uncover the specific mutations causing the disease, and physicians will use that information to select the right drug or predict which will be most effective. The approach has gained traction in the treatment of cancer and rare genetic diseases, but is not available for all patients and is yet to be widely applied to other diseases.

Precision medicine, using genomic information in a way that affects their clinical decisions about care, is already here and now, said Eric Green, director of the National Human Genome Research Institute, which carried out the Human Genome Project and is now working to apply that research to solve medical problems. This is not science fiction, but we are just starting to ascend this mountain. This will be a very long climb, but once we get to the top, you will see genomics being used all over the place.

Green said genetic sequencing in cancer and rare genetic disease treatment saves valuable time and money.

According to professor of medical oncology and Associate Director of the Yale Cancer Center Roy Herbst 84, Yale is already using genome sequencing to personalize treatments and predict the effectiveness of drugs for patients at the cancer center, allowing physicians to find the right drug, for the right patient, at the right time.

But the hope is for the practice to reach a larger population of cancer patients than it does now and ultimately to apply genome sequencing to other diseases.

According to Green, the latter will be more complicated. With diseases like diabetes, arthritis and hypertension, there is a complex interplay between environmental and genetic factors. But the complexity of figuring out how to use genetics in those more complex diseases makes for an even stronger argument to create the Precision Medical Initiative, he added.

Dean of the Yale School of Medicine Robert Alpern said that although the possibility to improve treatment for cancer and other diseases is there, more funding is still needed.

Were at this somewhat frustrating point where the science has never been in a better position to create ways for us to cure diseases that, frankly, when I went to medical school I thought could never be cured, and now theres not enough money, he said. The NIH budget just doesnt keep up with inflation. Were at a point where we can do so much and the money has never been so limited.

Alpern added that Yale is a leader in the use of genomics in personalized medicine the University even has a genome center on West Campus and is primed to turn additional funding into breakthroughs.

Continued here:

A promising personalized medicine initiative, but little funding

Systems to identify treatment targets for cancer and rare diseases

In recent months, several national initiatives for personalized medicine have been announced, including the recently launched precision medicine initiative in the US, driven by rapid advances in genomic technologies and with the promise of cheaper and better healthcare. Significant challenges remain, however, in the management and analysis of genetic information and their integration with patient data. The sheer scale and complexity of this data, generated using cutting-edge technologies such as next generation DNA sequencing, requires the development of new computer algorithms and systems that can mine this data to get actionable knowledge.

Now, scientists at A*STAR's Genome Institute of Singapore (GIS) have reported another breakthrough in the development of expert systems that can trawl large datasets, integrating complex disease information to guide doctors in the diagnosis and treatment of diseases. The latest in this series is the development of a system called OncoIMPACT that combines cancer omics data and models learned from hundreds of patients to better sift through genetic mutations and pick potentially causal ones.

The lead investigator in this study, Dr Niranjan Nagarajan, Associate Director of Computational and Systems Biology at the GIS, noted, "We are particularly excited about OncoIMPACT's ability to take into account the unique genetic makeup of each patient to predict treatment targets. It allows us to crunch massive cancer genome datasets in an integrative and model-driven fashion to distill them down to the few key driver mutations."

Assistant Professor Johannes Schumacher from the Institute of Human Genetics at the University of Bonn, added: "The integration of different 'omics' datasets for the identification of cancer driver genes is a challenge. OncoIMPACT fills a gap in integrative analyses and provides the opportunity to revisit large complex datasets for the identification of disease driving genes."

The team of researchers at A*STAR have applied OncoIMPACT to more than a thousand cancers such as melanomas, glioblastomas, prostate, bladder and ovarian cancers, and are in the process of building a complete map of driver mutations across cancers. They also demonstrated a proof-of-concept in this study for using driver mutation signatures to predict clinical outcomes for cancer patients. This is an exciting alternative to currently available tests based on RNA and protein levels as DNA can be more reliably assayed, and the team plans to develop this work further.

Dr Nagarajan remarked, "Our hope is to create a resource for cancer researchers and clinicians in Singapore and around the world. We envisage a future where expert systems such as OncoIMPACT can leverage genomic data generated worldwide and contribute to personalised and targeted medicine in Singapore."

Dr Gopal Iyer, Principal Investigator of the Cancer Therapeutics Research Laboratory at the National Cancer Centre of Singapore (NCCS) noted, "With the availability of large amounts of genetic data, it is difficult to focus our attention on the real cause and drivers in cancers. There are a number of algorithms that help narrow this search down in groups of cancers. OncoIMPACT, however, is different as it can focus these analyses on a single patient. This is the first step for true treatment individualisation: if we can uncover the drivers behind a tumour in a specific patient, we can ask if this can then be treated with specific drugs."

OncoIMPACT is the latest in the series of expert systems from the GIS and follows the recent publication of Phen-Gen -- the first such system to cross-reference patient's symptoms with genome sequence to detect causal genes for rare diseases. Both methods fall in the emerging area of integrative omics, where complex, multi-dimensional datasets are jointly analysed with sophisticated algorithms to reveal novel biological and medical insights.

Story Source:

The above story is based on materials provided by Biomedical Sciences Institutes (BMSI). Note: Materials may be edited for content and length.

Read more:

Systems to identify treatment targets for cancer and rare diseases

Studies Find More Genetic Links to Obesity

Latest Diet & Weight Management News

WEDNESDAY, Feb. 11, 2015 (HealthDay News) -- New research offers more evidence that genes play a significant role in obesity.

The findings may help explain why some people are more likely to put on extra pounds and develop obesity-linked conditions, the investigators said.

The researchers analyzed genetic samples from more than 300,000 people and identified more than 140 locations across their sets of DNA that play a role in obesity. They also pinpointed new biological pathways that play important roles in body weight and fat distribution.

The findings appear in two companion papers published Feb. 11 in the journal Nature.

This is the first step toward identifying individual genes involved in body shape and size, the researchers said. The proteins produced by the genes could offer targets for the development of new drugs to fight obesity.

One of the papers focused on genes that affect where fat is stored in the body, which affects health risk. For example, people with more belly fat are more likely to have metabolic conditions such as type 2 diabetes and cardiovascular disease than those with more fat in the hips or distributed throughout the body.

"We need to know these genetic locations because different fat deposits pose different health risks," senior author Karen Mohlke, a professor of genetics at the University of North Carolina School of Medicine, said in a University of Michigan Health System news release.

"If we can figure out which genes influence where fat is deposited, it could help us understand the biology that leads to various health conditions, such as insulin resistance/diabetes, metabolic syndrome and heart disease," she explained.

The other paper looked at the link between genes and body mass index (BMI), an estimate of body fat based on height and weight. The researchers said they found 97 genetic associations linked to BMI. They also found that genetic locations associated with BMI are linked to areas that control factors such as appetite and energy use.

See the rest here:

Studies Find More Genetic Links to Obesity

More genetic links to obesity discovered

New research offers more evidence that genes play a significant role in obesity.

The findings may help explain why some people are more likely to put on extra pounds and develop obesity-linked conditions, the investigators said.

The researchers analyzed genetic samples from more than 300,000 people and identified more than 140 locations across their sets of DNA that play a role in obesity. They also pinpointed new biological pathways that play important roles in body weight and fat distribution.

The findings appear in two companion papers published Feb. 11 in the journal Nature.

Play Video

There is new concern over another possible effect of antibiotics: obesity. Dr. Martin Blaser talks to the "CBS This Morning" co-hosts about the l...

This is the first step toward identifying individual genes involved in body shape and size, the researchers said. The proteins produced by the genes could offer targets for the development of new drugs to fight obesity.

One of the papers focused on genes that affect where fat is stored in the body, which affects health risk. For example, people with more belly fat are more likely to have metabolic conditions such as type 2 diabetes and cardiovascular disease than those with more fat in the hips or distributed throughout the body.

"We need to know these genetic locations because different fat deposits pose different health risks," senior author Karen Mohlke, a professor of genetics at the University of North Carolina School of Medicine, said in a University of Michigan Health System news release.

"If we can figure out which genes influence where fat is deposited, it could help us understand the biology that leads to various health conditions, such as insulin resistance/diabetes, metabolic syndrome and heart disease," she explained.

Original post:

More genetic links to obesity discovered

New option for Jewish genetic testing

Image via shutterstock.com

When a Jewish couple is planning their wedding or anticipating starting a family, they probably arent thinking much about rare genetic conditions. But JScreen, an educational and screening program, urges couples to add genetic testing to their to-do list. And by offering home-based testing, JScreen hopes to eliminate any obstacles to this process.

Based at Emory Universitys Department of Human Genetics, JScreen (jscreen.org) provides a Web-based portal for individuals to request a genetic-screening kit. Participants provide a saliva sample most genetic tests involve a blood draw and mail it back for analysis. Before receiving the kit, participants must view an educational video and enter health information that is reviewed by an Emory genetic counselor.

We all carry [recessive genes for] various genetic diseases. We just dont know what they are, said Karen Grinzaid, a genetic counselor and instructor at Emory University School of Medicine and the senior director of outreach initiatives for JScreen.

The problem occurs when both parents are carriers of the same disease. In that case, each of their offspring has a 25 percent chance of manifesting the condition.

According to Emorys Department of Human Genetics, about one in five Ashkenazi Jews in the U.S. carries a genetic disease. However, most dont have a family history of the disease and are unaware of their status of carriers. In fact, 80 percent of babies with genetic diseases are born to parents with no known family history of that disease.

The only way to know if you are a carrier for a Jewish genetic disease is to have an affected child or be screened, Grinzaid said. For the vast majority of couples, genetic screening gives couples reassurance that theyre not at risk.

Saliva samples returned to Emorys lab are tested for 40 diseases prevalent in the Jewish community. Nineteen of them are more common in Ashkenazi populations, and 21 of them are common in Jews of Sephardic or Mizrahi (Middle Eastern) origins. Testing for an additional 47 diseases found in the general population is available at no extra cost. Many of the diseases included in the tests are fatal, and all impact the individuals quality of life.

Results take less than four weeks. If they are negative, individuals are notified via email. Those who are identified as carriers speak via phone or videoconference to an Emory University genetic counselor about their results and options. They might also be referred to a local genetic counselor for more extensive counseling. Grinzaid said that about 2 percent of couples will be found to be carriers of the same disease.

If both members of a couple carry the same genetic disease, they have several options. One is to undergo in-vitro fertilization using pre-implantation genetic diagnosis. This technology allows embryos to be tested for the affected gene before being implanted. Other options include using a donor egg or sperm, or pursuing adoption.

Here is the original post:

New option for Jewish genetic testing

An International Genetic Study Confirms the History of the Druze Community

Contact Information

Available for logged-in reporters only

Newswise A first of its kind genetic study confirms the history of the Druze community: The community began to form genetically in the 11th century AD, and there has since been no genetic impact of other ethnic groups on the community. This is according to a new study conducted by a team of researchers led by Prof. Gil Atzmon of the University of Haifa, Prof. Jamal Zidan of the Ziv Medical Center, Zefat, and Prof. Eitan Friedman of the Chaim Sheba Medical Center, Tel Hashomer. This is the first genetic study to discover that the Druze community has genetic origins in the 11th century AD, said Professor Atzmon of the University of Haifa. This genetic finding correlates with the Druze communitys beliefs regarding their origin.

Traditionally, the Druze people believe that their community was founded in the 11th century AD as a new religious movement under the sixth caliph of the Fatimid Dynasty of Egypt. There are currently 1.5 million Druze around the world, residing mainly in Syria and Lebanon, with the remainder in Israel and Jordan. According to Druze tradition, marriages take place only within the Druze community.

An international team of researchers was formed to perform this current study, published in the European Journal of Human Genetics Nature, which sought to examine whether the Druze people of today have a similar gene pool and if so, when that gene pool began to take shape. The head of the team, Prof. Atzmon of the University of Haifas Department of Human Biology and of the Department of Medicine and Genetics, the Albert Einstein College of Medicine, NY, together with Prof. Zidan, the director of the oncology department at Ziv Medical Center and of the Faculty of Medicine in the Galilee, Bar-Ilan University and Prof. Eitan Friedman of the Sackler School of Medicine, Tel Aviv University, were joined by Dr. Dan Ben-Avraham of the Department of Medicine and Genetics, Albert Einstein College of Medicine, NY, Dr. Shai Carmi of the Department of Computer Science, Columbia University, NY, and Dr. Taiseer Maray of the organization, Golan for Development.

The study included 120 participants from forty families. Twenty families were from the village of Beit Jan located in the Upper Galilee and twenty were from Majdal Shams, in the Golan Heights. The families were selected according to the origins of their extended families (clans), based on their family names and on information that was passed down orally from generation to generation. The mother, father and son of each family were genetically tested. All the families who participated in the study were from different clans so that the sample would be representative and it excluded first- or second-degree family relationships to any other participants in the study. These characteristics all significantly increased the studys genetic accuracy. In this study, we incorporated data that was published on the Druze of Lebanon, the Carmel Mountain region and various other populations in order to test the genetic structure of the Druze population relative to other populations, said Prof. Zidan.

The results indicated that the Druze do indeed share a high genetic similarity that significantly distinguishes them from member of other groups and communities in the Middle East. When the researchers went back in time to discover when this genetic similarity began, they reached the 11th century AD, about 22-47 generations ago (there are differences of opinion over the duration of a generation). During this period a genetic bottleneck was formed, i.e., the genetic origin of many descendants came to an end, the communitys population decreased and the individuals in the population became more alike genetically. According to Prof. Atzmon, their research findings limit the ancestors of the Druze community to several hundred families, who founded the community in the 11th century AD. The researchers also found that there is no evidence of new genes entering the Druze gene pool over the last 1,000 years. In other words, no additional groups from the outside joined this community. In addition, the researchers found evidence of genetic differences between Druze populations from different regions: Lebanon, the Golan Hights, the Upper Galilee and the Carmel Mountain. This strengthens the evidence that marriages take place only within each clan.

When they went further back in time, the researchers discovered another interesting finding. It came to light that, 500 years prior to the beginning of the Druze religion, around the 6th century AD and at the time of the birth of Islam, a genetic group began to take shape that formed the genetic basis of the Druze communitys ancestors. According to this study, the Druze genome is largely similar to the genome of other Arab populations in the Middle East. They also found a few genetic elements in the Druze genome that originated from Europe, Central and South Asia (the Iran region) and Africa.

Our next step is to try to identify the genetic component of common diseases in this sector using the traditional family structure in a study that will allow genetic decoding of regular genetic diseases and provide data on diseases that have a genetic basis, such as cancer and diabetes. We are also planning similar studies in the future of the Muslim and Christian populations in Israel, Prof. Friedman concluded.

See the rest here:

An International Genetic Study Confirms the History of the Druze Community

New Genes Mean the Future of Obesity Treatment Could Get Personal

TIME Health Obesity New Genes Mean the Future of Obesity Treatment Could Get Personal Getty Images Scientists have uncovered a trove of new genetic targets that could lead to better treatments for obesity

It took the genomes of nearly 340,000 people and more than 400 researchers in two dozen countries, but we now have the most comprehensive picture so far of the genetic contributors to obesity.

Two new papers in the journal Nature describe the results of two studies that connected the obesity-related factors of body mass index (the ratio between height and weight) and fat distribution to their potential genetic drivers. The studies did not isolate specific genesat least not yetbut identified areas in the human genome where people with different BMIs and different patterns of fat distribution varied in their genetic code. Those variants will lead scientists to the genes they code for, and eventually to how those genes work in contributing to obesity.

MORE: Healthy-Obesity Gene FoundBut Genes Arent Everything

I think we have so many more opportunities now to learn about the biology of obesity through genetic contributions to these traits, says Karen Mohlke, professor of genetics at University of North Carolina and the senior author of the report focusing on body fat distribution.

Those genetic clues may yield new weight-management treatments that are both more powerful and more personalized. What the data supports is the fact that there are a lot of different causes of obesity, says Dr. Elizabeth Speliotes, assistant professor of internal medicine and computational medicine and bioinformatics at the University of Michigan and senior author of the paper on body mass index. If youre hoping for one cause of obesity, thats not reality. What causes you to be obese is probably slightly different from what causes me to be obese.

Currently, however, all obesity is treated pretty much the same way. With the new knowledge gleaned from the genetics of whats driving different types of obesity, that may change.

MORE: Gym vs. Genes: How Exercise Trumps Obesity Genes

In the study involving factors contributing to BMI, Speliotes and her team discovered 97 genetic regions, or loci that account for nearly 3% of the variation among people on BMI. Of those, 56 are entirely new. Many of the regions are in areas that code for nervous system functions, or brain systems. Some arent so surprisingthey confirm previous studies that have implicated genetic regulators of areas that control appetite, for examplebut others were more unexpected. They involved regions responsible for learning, memory and even emotional regulation, hinting that some of weight and obesity may be tied to the addiction and reward pathways that help to reinforce behaviors like eating with feelings of pleasure and satisfaction. There were definitely a lot more loci involving the brain than I would have guessed, says Dr. Joel Hirschhorn, director of the center for basic and translational obesity research at Boston Childrens Hospital and Harvard Medical School and one of the co-authors. That makes obesity much more of a neurobehavioral disorder than just the fact that your fat cells are more efficient or less efficient.

MORE: Study Identifies Four New Genetic Markers For Severe Childhood Obesity

More here:

New Genes Mean the Future of Obesity Treatment Could Get Personal

Largest Ever Genome-Wide Study Strengthens Genetic Link to Obesity

Contact Information

Available for logged-in reporters only

Newswise ANN ARBOR, Mich. There are many reasons why people gain different amounts of weight and why fat becomes stored in different parts of their bodies. Now researchers are homing in on genetic reasons. Their findings, part of the largest genome-wide study to date, were published in two companion papers today in the journal Nature.

By analyzing genetic samples from more than 300,000 individuals to study obesity and body fat distribution, researchers in the international Genetic Investigation of Anthropometric Traits (GIANT) Consortium completed the largest study of genetic variation to date, and found over 140 locations across the genome that play roles in various obesity traits.

By applying novel computational methods to the genetic results, they discovered new biological pathways that are important in controlling body weight and fat distribution.

This work is the first step toward finding individual genes that play key roles in body shape and size. The proteins these genes help produce could become targets for future drug development.

Obesity is a global public health burden that affects millions of people. Yet, there are no long-term treatments.

Waist-to-hip ratios key for health risk One paper focused on where fat is stored in the body, one determinant of health risk. One of the observable traits linked to the genetic locations was waist-to-hip circumference ratio. People with waistlines larger than hip circumferences have more belly fat surrounding their abdominal organs. This makes them more likely to have metabolic conditions, such as type-2 diabetes, and cardiovascular problems than do people with body fat concentrated more in the hip area or distributed equally throughout the body.

We need to know these genetic locations because different fat depots pose different health risks, says Karen Mohlke, Ph.D., professor of genetics at the University of North Carolina School of Medicine and senior author of the paper that examined waist-to-hip ratio of fat distribution. If we can figure out which genes influence where fat is deposited, it could help us understand the biology that leads to various health conditions, such as insulin resistance/diabetes, metabolic syndrome, and heart disease.

The genetic locations associated with fat depots are associated with genes previously identified as being important for the creation of adipose tissue. Researchers also determined that 19 of the fat distribution genetic locations had a stronger effect in women; one had a stronger effect in men.

Original post:

Largest Ever Genome-Wide Study Strengthens Genetic Link to Obesity

Precision Medicine for Mental Disorders

Precision medicine seems to be the new hot topic in the research world. President Obama spoke about precision medicine in his State of the Union speech on January 20, his budget released today requests $215M for precision medicine, and NIH just announced plans for a study of a million or more volunteers to explore precision medicine. What precisely is it? The White House website has a useful definition: getting the right treatment at the right time to the right person. The President, in an event devoted to precision medicine in the East Room last Friday [January 30, see video, below], told the story of ivacaftor, a drug that effectively treats the underlying causenot the symptomsof cystic fibrosis, but works in only 4% of patients who have a specific mutation in the gene causing this disease.

Most of the conversation about precision medicine focuses on cancer. Because cancer is a disease of genetic mutations leading to unregulated cell division, defining the precise mutations in the affected tissue have already led to breakthrough treatments for both blood and solid tissue cancers. In fact, the same mutation can occur in different parts of the body, so cancer is increasingly diagnosed in terms of its genetic and molecular signature rather than the tissue of origin. Part of the proposed precision medicine plan will involve scaling up efforts at the National Cancer Institute to find these mutations and to develop drugs or biologics as treatments.

What does precision medicine mean for mental health? Our version is the Research Domain Criteria (RDoC) project, which aims to develop more precise diagnostic categories based on biological, psychological, and socio-cultural variables. It is certainly possible that we may find specific mutations in relevant brain circuits that explain some cases of schizophrenia, bipolar disorder, or autism, just as mutations in the tumor explain cancer. NIMH has supported research on inherited genetic risk for several years; a new initiative on another class of mutations, somatic mosaicism (the term for mutations that develop after fertilization), will launch this year. But more likely, precision medicine for mental disorders will not come from a single genomic glitch. Rather, like many other areas of medicine, many genes each contribute only a small amount of vulnerability as part of an overall risk profile that includes life experiences, neurodevelopment, and social and cultural factors. RDoC assumes that we will need many kinds of data to reach precision, more like triangulating to find your position on a map. These data will draw from many sources, including symptoms, genotype, physiology, cognitive assessment, family dynamics, environmental exposures, and cultural background.

I know that RDoC sounds more complex than the cancer version of precision medicine, but that is the nature of the problem. For now, we need to embrace the complexity to identify the simpler, actionable categories that can be used in the clinic. The rationale for this approach is no different from what the President talked about for cancer or cystic fibrosisgetting the right treatment at the right time to the right person.

View original post here:

Precision Medicine for Mental Disorders

Another look at the potential for three-parent babies

Members of England's Parliament passed legislation on Feb. 3 that allows the use of DNA from a third-party female donor to be used in a human embryo -- a new move toward eliminating genetic disease.

The technique could help babies with mitochondrial disease, which affects one in every 6,500 babies and can be fatal. Mitochondria, found in nearly all of the body's cells, converts food into usable energy and contains DNA that does not affect other personal traits (such as appearance). When defective, it can lead to brain damage, heart failure, blindness and muscle wasting.

The process would replace the harmful material in a woman's egg prior to conception, mixing the DNA of the two parents with a donor woman's healthy mitochondria.

This procedure, however, raises a number of ethical issues and objections, as it involves experimentation with human reproduction and requires in vitro fertilization, the church's "default" argument against the technique, wrote Jack Mahoney for The Tablet.

But the church also once opposed organ transplants for requiring "self-mutilation," Mahoney noted. "Few people would now accept that extremely partial analysis as an adequate description of what many rightly view as an act of human solidarity," he wrote.

Help keep NCR going! We rely on donations to bring you the latest news. Donate today.

The distinction between genetic transplants and a "genetic apocalypse" likens in positive or negative genetic medicine. "It need not be the case that the wish to prevent an individual, or even the human gene pool, from suffering a particular genetic malady will inevitably usher humanity into Aldous Huxley's Brave New World," Mahoney wrote, referring to a 1932 novel about reproductive technology.

Negative, or preventive, genetic medicine aims to eliminate deficiencies or diseases in an individual or possibly for generations to come. Positive genetic medicine, or genetic enhancement, aspires to improve individuals by adding genes based on preferences, making the individual more personally or socially advantageous. When geared for the individual's sake, it is "somatic therapy," whereas "germ line therapy" refers to the introduction of genetic changes in the reproductive system that will eventually continue through succeeding generations.

But the uneasiness around substituting various genes, Mahoney said, implies "the view that humans are simply the product of their genes, now including someone else's, and that their personality and behaviour are determined by their genetic make-up, leaving little, if any, room for personal freedom of choice and self-determination on the part of the individual."

Consider how external factors -- environmental, economic, and the unconscious -- affect human behavior. "Being predisposed is not the same as being predetermined," Mahoney wrote.

Original post:
Another look at the potential for three-parent babies

Medical genetics of Jews – Wikipedia, the free encyclopedia

The medical genetics of Jews is the study, screening, and treatment of genetic disorders more common in particular Jewish populations than in the population as a whole.[1] The genetics of Ashkenazi Jews have been particularly well-studied, resulting in the discovery of many genetic disorders associated with this ethnic group. In contrast, the medical genetics of Sephardic Jews and Mizrahi Jews are more complicated, since they are more genetically diverse and consequently no genetic disorders are more common in these groups as a whole; instead, they tend to have the genetic diseases common in their various countries of origin.[1][2] Several organizations, such as Dor Yeshorim,[3] offer screening for Ashkenazi genetic diseases, and these screening programs have had a significant impact, in particular by reducing the number of cases of TaySachs disease.[4]

Different ethnic groups tend to suffer from different rates of hereditary diseases, with some being more common, and some less common. Hereditary diseases, particularly hemophilia, were recognized early in Jewish history, even being described in the Talmud.[5] However, the scientific study of hereditary disease in Jewish populations was initially hindered by scientific racism, which believed in racial supremacism.[6][7]

However, modern studies on the genetics of particular ethnic groups have the tightly defined purpose of avoiding the birth of children with genetic diseases, or identifying people at particular risk of developing a disease in the future.[6] Consequently, the Jewish community has been very supportive of modern genetic testing programs, although this unusually high degree of cooperation has raised concerns that it might lead to the false perception that Jews are more susceptible to genetic diseases than other groups of people.[5]

However, most populations contain hundreds of alleles that could potentially cause disease and most people are heterozygotes for one or two recessive alleles that would be lethal in a homozygote.[8] Although the overall frequency of disease-causing alleles does not vary much between populations, the practice of consanguineous marriage (marriage between second cousins or closer relatives) is common in some Jewish communities, which produces a small increase in the number of children with congenital defects.[9]

According to Daphna Birenbaum Carmeli at the University of Haifa, Jewish populations have been studied more thoroughly than most other human populations because:[10]

The result is a form of ascertainment bias. This has sometimes created an impression that Jews are more susceptible to genetic disease than other populations. Carmeli writes, "Jews are over-represented in human genetic literature, particularly in mutation-related contexts."[10] Another factor that may aid genetic research in this community is that Jewish culture results in excellent medical care, which is coupled to a strong interest in the community's history and demography.[11]

This set of advantages have led to Ashkenazi Jews in particular being used in many genetic studies, not just in the study of genetic diseases. For example, a series of publications on Ashkenazi centenarians established their longevity was strongly inherited and associated with lower rates of age-related diseases.[12] This "healthy aging" phenotype may be due to higher levels of telomerase in these individuals.[13]

The most detailed genetic analysis study of Ashkenazi was published in September 2014 by Shai Carmon and his team at Columbia University. The results of the detailed study show that today's 10 million Ashkenai Jews descend from a population only 350 individuals who lived about 600-800 years ago. That population derived from both Europe and the Middle East. [14]There is evidence that the population bottleneck may have allowed deleterious alleles to become more prevalent in the population due to genetic drift.[15] As a result, this group has been particularly intensively studied, so many mutations have been identified as common in Ashkenazis.[16] Of these diseases, many also occur in other Jewish groups and in non-Jewish populations, although the specific mutation which causes the disease may vary between populations. For example, two different mutations in the glucocerebrosidase gene causes Gaucher's disease in Ashkenazis, which is their most common genetic disease, but only one of these mutations is found in non-Jewish groups.[4] A few diseases are unique to this group; for example, familial dysautonomia is almost unknown in other populations.[4]

TaySachs disease, a fatal illness of children that causes mental deterioration prior to death, was historically more prevalent among Ashkenazi Jews,[18] although high levels of the disease are also found in some Pennsylvania Dutch, southern Louisiana Cajun, and eastern Quebec French Canadian populations.[19] Since the 1970s, however, proactive genetic testing has been quite effective in eliminating TaySachs from the Ashkenazi Jewish population.[20]

Gaucher's disease, in which lipids accumulate in inappropriate locations, occurs most frequently among Ashkenazi Jews;[21] the mutation is carried by roughly one in every 15 Ashkenazi Jews, compared to one in 100 of the general American population.[22] Gaucher's disease can cause brain damage and seizures, but these effects are not usually present in the form manifested among Ashkenazi Jews; while sufferers still bruise easily, and it can still potentially rupture the spleen, it generally has only a minor impact on life expectancy.

Read more here:

Medical genetics of Jews - Wikipedia, the free encyclopedia

Genetic disorder – Wikipedia, the free encyclopedia

Genetic disorder Classification and external resources MeSH D030342

A genetic disorder is an illness caused by one or more abnormalities in the genome, especially a condition that is present from birth (congenital). Most genetic disorders are quite rare and affect one person in every several thousands or millions.

Genetic disorders may or may not be heritable, i.e., passed down from the parents' genes. In non-heritable genetic disorders, defects may be caused by new mutations or changes to the DNA. In such cases, the defect will only be heritable if it occurs in the germ line. The same disease, such as some forms of cancer, may be caused by an inherited genetic condition in some people, by new mutations in other people, and mainly by environmental causes in still other people. Whether, when and to what extent a person with the genetic defect or abnormality will actually suffer from the disease is almost always affected by environmental factors and events in the person's development.

Some types of recessive gene disorders confer an advantage in certain environments when only one copy of the gene is present.[1]

A single gene disorder is the result of a single mutated gene. Over 4000 human diseases are caused by single gene defects.[4] Single gene disorders can be passed on to subsequent generations in several ways. Genomic imprinting and uniparental disomy, however, may affect inheritance patterns. The divisions between recessive and dominant types are not "hard and fast", although the divisions between autosomal and X-linked types are (since the latter types are distinguished purely based on the chromosomal location of the gene). For example, achondroplasia is typically considered a dominant disorder, but children with two genes for achondroplasia have a severe skeletal disorder of which achondroplasics could be viewed as carriers. Sickle-cell anemia is also considered a recessive condition, but heterozygous carriers have increased resistance to malaria in early childhood, which could be described as a related dominant condition.[5] When a couple where one partner or both are sufferers or carriers of a single gene disorder and wish to have a child, they can do so through in vitro fertilization, which means they can then have a preimplantation genetic diagnosis to check whether the embryo has the genetic disorder.[6]

Only one mutated copy of the gene will be necessary for a person to be affected by an autosomal dominant disorder. Each affected person usually has one affected parent.[7] The chance a child will inherit the mutated gene is 50%. Autosomal dominant conditions sometimes have reduced penetrance, which means although only one mutated copy is needed, not all individuals who inherit that mutation go on to develop the disease. Examples of this type of disorder are Huntington's disease,[8]neurofibromatosis type 1, neurofibromatosis type 2, Marfan syndrome, hereditary nonpolyposis colorectal cancer, and hereditary multiple exostoses,Tuberous sclerosis, Von Willebrand disease, acute intermittent porphyria which is a highly penetrant autosomal dominant disorder. Birth defects are also called congenital anomalies.

Two copies of the gene must be mutated for a person to be affected by an autosomal recessive disorder. An affected person usually has unaffected parents who each carry a single copy of the mutated gene (and are referred to as carriers). Two unaffected people who each carry one copy of the mutated gene have a 25% risk with each pregnancy of having a child affected by the disorder. Examples of this type of disorder are Albinism, Medium-chain acyl-CoA dehydrogenase deficiency, cystic fibrosis, sickle-cell disease, Tay-Sachs disease, Niemann-Pick disease, spinal muscular atrophy, and Roberts syndrome. Certain other phenotypes, such as wet versus dry earwax, are also determined in an autosomal recessive fashion.[9][10]

X-linked dominant disorders are caused by mutations in genes on the X chromosome. Only a few disorders have this inheritance pattern, with a prime example being X-linked hypophosphatemic rickets. Males and females are both affected in these disorders, with males typically being more severely affected than females. Some X-linked dominant conditions, such as Rett syndrome, incontinentia pigmenti type 2, and Aicardi syndrome, are usually fatal in males either in utero or shortly after birth, and are therefore predominantly seen in females. Exceptions to this finding are extremely rare cases in which boys with Klinefelter syndrome (47,XXY) also inherit an X-linked dominant condition and exhibit symptoms more similar to those of a female in terms of disease severity. The chance of passing on an X-linked dominant disorder differs between men and women. The sons of a man with an X-linked dominant disorder will all be unaffected (since they receive their father's Y chromosome), and his daughters will all inherit the condition. A woman with an X-linked dominant disorder has a 50% chance of having an affected fetus with each pregnancy, although it should be noted that in cases such as incontinentia pigmenti, only female offspring are generally viable. In addition, although these conditions do not alter fertility per se, individuals with Rett syndrome or Aicardi syndrome rarely reproduce.[citation needed]

X-linked recessive conditions are also caused by mutations in genes on the X chromosome. Males are more frequently affected than females, and the chance of passing on the disorder differs between men and women. The sons of a man with an X-linked recessive disorder will not be affected, and his daughters will carry one copy of the mutated gene. A woman who is a carrier of an X-linked recessive disorder (XRXr) has a 50% chance of having sons who are affected and a 50% chance of having daughters who carry one copy of the mutated gene and are therefore carriers. X-linked recessive conditions include the serious diseases hemophilia A, Duchenne muscular dystrophy, and Lesch-Nyhan syndrome, as well as common and less serious conditions such as male pattern baldness and red-green color blindness. X-linked recessive conditions can sometimes manifest in females due to skewed X-inactivation or monosomy X (Turner syndrome).

Y-linked disorders, also called holandric disorders, are caused by mutations on the Y chromosome. These conditions display may only be transmitted from the heterogametic sex (e.g. male humans) to offspring of the same sex. More simply, this means that Y-linked disorders in humans can only be passed from men to their sons; females can never be affected because they do not possess Y allosomes.

Follow this link:

Genetic disorder - Wikipedia, the free encyclopedia

Genetic Testing – Health Insurance, Dental Insurance …

Clinical Policy Bulletin: Genetic Testing

Aetna considers genetic testing medically necessary to establish a molecular diagnosis of an inheritable disease when all of the following are met:

The member displays clinical features, or is at direct risk of inheriting the mutation in question (pre-symptomatic); and

The result of the test will directly impact the treatment being delivered to the member; and

Achondroplasia (FGFR3) Albinism Alpha-1 antitrypsin deficiency (SERPINA1) Alpha thalassemia/Hb Bart hydrops fetalis syndrome/HbH disease** (HBA1/HBA2, alpha globin 1 and alpha globulin 2) Angelman syndrome (GABRA, SNRPN Beta thalassemia** (beta globin) Bloom syndrome (BLM) CADASIL (see below) Canavan disease (ASPA (aspartoacylase A)) Charcot-Marie Tooth disease (PMP-22) Classical lissencephaly Congenital adrenal hyperplasia/21 hydroxylase deficiency (CYP21A2)* Congenital amegakaryocytic thrombocytopenia Congenital central hypoventilation syndrome (PHOX2B) Congenital muscular dystrophy type 1C (MDC1C) (FKRP (Fukutin related protein)) Crouzon syndrome (FGFR2, FGFR3) Cystic fibrosis (CFTR) (see below) Dentatorubral-pallidoluysian atrophy Duchenne/Becker muscular dystrophy (dystrophin) Dysferlin myopathyEhlers-Danlos syndrome Emery-Dreifuss muscular dystrophy (EDMD1, 2, and 3) Fabry disease Factor V Leiden mutation (F5 (Factor V)) Factor XIII deficiency, congenital (F13 (Factor XIII beta globulin)) Familial adenomatous polyposis coli (APC) (see below) Familial dysautonomia (IKBKAP) Familial hypocalciuric hypercalcemia (see below)Familial Mediterranean fever (MEFV) Fanconi anemia (FANCC, FANCD) Facioscapulohumeral muscular dystrophy (FSHMD1A) Fragile X syndrome, FRAXA (FMR1) (see below) Friedreich's ataxia (FRDA (frataxin)) Galactosemia (GALT) Gaucher disease (GBA (acid beta glucosidase)) Gitelman's syndromeHemoglobin E thalassemia ** Hemoglobin S and/or C ** Hemophilia A/VWF (F8 ( Factor VIII)) Hemophilia B (F9 (Factor IX)) Hereditary amyloidosis (TTR variants) Hereditary deafness (GJB2 (Connexin-26, Connexin-32 )) Hereditary hemorrhagic telangiectasia (HHT) Hereditary hemochromatosis (HFE) (see below) Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome (fumarate hydratase (FH) gene) Hereditary neuropathy with liability to pressure palsies (HNPP) Hereditary non-polyposis colorectal cancer (HNPCC) (MLH1, MSH2, MSH6. MSI) ( see below) Hereditary pancreatitis (PRSS1) (see below) Hereditary paraganglioma (SDHD, SDHB)

Hereditary polyposis coli (APC) Hereditary spastic paraplegia 3 (SPG3A) and 4 (SPG4, SPAST) Huntington's disease (HTT, HD(Huntington)) Hypochondroplasia (FGFR3) Hypertrophic cardiomyopathy (see below) Jackson-Weiss syndrome (FGFR2)Kallmann syndrome (FGFR1) Kennedy disease (SBMA) Leber hereditary optic neuropathy (LHON) Leigh Syndrome and NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) Long QT syndrome (see below) Limb girdle muscular dystrophy (LGMD1, LGMD2) (FKRP (Fukutin related protein)) Malignant hyperthermia (RYR1) Maple syrup urine disease (branched-chain keto acid dehydrogenase E1) Marfans syndrome (TGFBR1, TGFBR2) McArdle's diseaseMedium chain acyl coA dehydrogenase deficiency (ACADM) Medullary thyroid carcinoma MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) (MTTL1, tRNAleu) Mucolipidosis type IV (MCOLN1, mucolipin 1) Mucopolysaccharidoses type 1 (MPS-1) Muenke syndrome (FGFR3) Multiple endocrine neoplasia type 1 Muscle-Eye-Brain disease (POMGNT1) MYH-associated polyposis (MYH) (see below) Myoclonic epilepsy (MERRF) (MTTK (tRNAlys)) Myotonic dystrophy (DMPK, ZNF-9) Neimann-Pick disease, type A(SMPD1, sphingomyelin phosphodiesterase) Nephrotic syndrome, congenital (NPHS1, NPHS2) Neurofibromatosis type 1 (NF1, neurofibromin) Neurofibromatosis type 2 (Merlin) Neutropenia, congenital cyclic Phenylketonuria (PAH) Pfeiffer syndrome (FGFR1) Prader-Willi-Angelman syndrome (SNRPN, GABRA5, NIPA1, UBE3A, ANCR, GABRA ) Primary dystonia (TOR1A (DYT1)) Prothrombin (F2 (Factor II,20210G> A mutation)) Pyruvate kinase deficiency (PKD) Retinoblastoma (Rh) Rett syndrome (FOXG1, MECP2) Saethre-Chotzen syndrome (TWIST, FGFR2) SHOX-related short stature (see below) Smith-Lemli-Opitz syndrome Spinal muscular atrophy (SMN1, SMN2 ) Spinocerebellar ataxia (SCA types 1, 2, 3 (MJD), 6 (CACNA1A), 7, 8, 10, 17 and DRPLA) Tay-Sachs disease (HEXA (hexosaminidase A)) Thanatophoric dysplasia (FGFR3) Von Gierke disease (G6PC, Glycogen storage disease, Type 1a) Von Hippel-Lindau syndrome (VHL) Walker-Warburg syndrome (POMGNT1) 22q11 deletion syndromes (DCGR (CATCH-22))

* Medically necessary if results of the adrenocortical profile following cosyntropin stimulation test are equivocal or for purposes of genetic counseling.

** Electrophoresis is the appropriate initial laboratory test for individuals judged to be at-risk for a hemoglobin disorder.

In the absence of specific information regarding advances in the knowledge of mutation characteristics for a particular disorder, the current literature indicates that genetic tests for inherited disease need only be conducted once per lifetime of the member.

Note: Genetic testing of Aetna members is excluded from coverage under Aetna's benefit plans if the testing is performed primarily for the medical management of other family members who are not covered under an Aetna benefit plan. In these circumstances, the insurance carrier for the family members who are not covered by Aetna should be contacted regarding coverage of genetic testing. Occasionally, genetic testing of tissue samples from other family members who are not covered by Aetna may be required to provide the medical information necessary for the proper medical care of an Aetna member. Aetna covers genetic testing for heritable disorders in non-Aetna members when all of the following conditions are met:

See the article here:

Genetic Testing - Health Insurance, Dental Insurance ...

Expanded Carrier Screening in Reproductive Medicine: New Joint Statement Is Released in Acog's Obstetrics & Gynecology

Contact Information

Available for logged-in reporters only

Newswise BETHESDA, Md., Feb. 5, 2015 /PRNewswire-USNewswire/ -- Carrier screening for inherited genetic disorders is an important part of preconception and prenatal care for the nearly 4 million women who give birth in the US annually. Carrier screening is meant to identify couples at risk for passing on such genetic conditions to their children. While there have been limitations to this approach in the past, new technology in genotyping and genetic sequencing allows for more efficient carrier screening of a greater number of conditions simultaneously.

In an important new statement, several of the nation's leading medical societies have collaborated to provide guidance on such advances and their use in reproductive medicine. The American College of Medical Genetics and Genomics (ACMG) along with the American College of Obstetricians and Gynecologists, the National Society of Genetic Counselors, the Society for Maternal-Fetal Medicine and Perinatal Quality Foundation have just released a new Joint Statement on "Expanded Carrier Screening in Reproductive Medicine - Points to Consider" published online ahead of print in Obstetrics & Gynecology ("the Green Journal") in Current Commentary at http://journals.lww.com/greenjournal/toc/publishahead.

Anthony R. Gregg, MD, FACOG, FACMG, vice-president, Clinical Genetics of the American College of Medical Genetics and Genomics and a co-author of the Joint Statement said, "This document is a sort of a blueprint of expanded carrier screening in clinical practice. It serves obstetric care providers by helping them navigate pretest information to share with patients and concepts applicable to posttest follow-up. Importantly, pitfalls surrounding expanded carrier screening are described. Readers will recognize that this document does not advocate for or against the universal implementation of expanded carrier screening. There is a paucity of scientifically sound information to guide professional organizations in taking a firm stance. For now currently available practice guidelines (summarized in the joint document) authored by ACMG and ACOG prevail and these represent a minimum screening standard. Professional organizations may, at a later time, determine whether and to what extent patients should be informed of expanded screening technology."

The five groups collaborated on the Joint Statement on Expanded Carrier Screening in order to provide education for clinicians and laboratories regarding the use of expanded genetic carrier screening in reproductive medicine. It states, "The current statement demonstrates an approach for health care providers and laboratories who wish to or who are currently offering expanded carrier screening to their patients."

While the new Joint Statement is not intended to replace existing practice guidelines and policy statements, it states that they "offer an opportunity for health care providers to better understand expanded carrier screening. Many more conditions, genes and variants are analyzed when expanded carrier screening is used compared with current screening approaches.... However, this approach introduces complexities that require special considerations."

ACMG President-Elect Gerald Feldman, MD, Ph.D., FACMG stated, "There are always advantages and disadvantages when a new technology is implemented, as is the case for expanded genetic testing. This document was written to provide a summary of the important points a physician should consider when discussing expanded carrier screening with his or her patient, because these tests offer testing for many more conditions than currently recommended by professional organizations. It is important that the patient fully understand and consent to such testing if they so choose. A referral to a genetics health care professional, such as a Board-certified clinical geneticist, should always be recommended when appropriate."

"Variation among people as to what they think justifies consideration when making reproductive decisions is varied and complicates generating a specific list of genes and variants that should be part of a test. Our goal for this document was to highlight the important aspects of genes and diseases that should be considered when developing expanded carrier screening panels, " said co-author Michael S. Watson, MS, Ph.D., FACMG, Executive Director of the American College of Medical Genetics and Genomics.

About the ACMG and ACMG Foundation Founded in 1991, the American College of Medical Genetics and Genomics (www.acmg.net) advances the practice of medical genetics and genomics by providing education, resources and a voice for more than 1750 biochemical, clinical, cytogenetic, medical and molecular geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG is the only nationally recognized medical organization dedicated to improving health through the practice of medical genetics and genomics. The College's mission includes the following goals: 1) to define and promote excellence in the practice of medical genetics and genomics and to facilitate the integration of new research discoveries into medical practice; 2) to provide medical genetics and genomics education to fellow professionals, other healthcare providers, and the public; 3) to improve access to medical genetics and genomics services and to promote their integration into all of medicine; and 4) to serve as advocates for providers of medical genetics and genomics services and their patients. Genetics in Medicine, published monthly, is the official ACMG peer-reviewed journal. ACMG's website (www.acmg.net) offers a variety of resources including Policy Statements, Practice Guidelines, Educational Resources, and a Find a Geneticist tool. The educational and public health programs of the American College of Medical Genetics are dependent upon charitable gifts from corporations, foundations, and individuals through the ACMG Foundation for Genetic and Genomic Medicine (www.acmgfoundation.org.)

Read the rest here:

Expanded Carrier Screening in Reproductive Medicine: New Joint Statement Is Released in Acog's Obstetrics & Gynecology

Study finds genetic mutation behind most common breast cancer

The study found that one variant increased the risk of oestrogen receptor positive disease by 14 per cent, while a second raised the chance by 11 per cent.

Researchers said the finding provided important clues about the way disease is caused, implicating a gene called KLF4, which is thought to help control the way cells grow and divide.

The research involved scientists from more than 130 institutions worldwide, including the London School of Hygiene and Tropical Medicine, and the University of Cambridge.

Researchers were looking for one-letter differences in DNA code that were more likely to be found in women with breast cancer than those without the disease, using a state-of-the-art genetic technique called fine mapping.

Study leader Dr Nick Orr said: "Our study zoomed in on an area of our genome that we knew was linked to breast cancer risk, and has identified two new genetic variants that add significantly to our knowledge about the genetic causes of the disease.

"The variants we identified are specifically associated with the most common, oestrogen receptor positive, form of breast cancer.

"The more genetic risk factors for breast cancer we discover, of which there are currently more than 80, the more accurately we will be able predict who is at risk of getting the disease. Ultimately this will be vital for designing preventative strategies against breast cancer."

Dr Emma Smith, senior science information officer at Cancer Research UK, praised the results.

She said: "Thanks to modern technology we're building an increasingly detailed picture of the small variations in DNA that can influence a woman's risk of breast cancer.

"The next challenges are understanding the biology underpinning their effects, so we can use this information to predict individual risk more accurately, improve screening and find better ways to treat and prevent breast cancer."

Read the rest here:

Study finds genetic mutation behind most common breast cancer

Obamas 'Precision Medicine' Database: How Safe And Private Is The Patient Data?

Scientific progress sometimes requires a leap of faith. And patients who volunteer their records to a national genomic database under President Obamas new initiative for precision medicine will be taking a big one.

In the young field of genomics, scientists are still drawing the ethical road map for open-ended exploration and realizing the privacy implications for what they might uncover. In the meantime, those who sign up for genomic studies are essentially along for the ride.

President Obama is asking Congress to embark down a new path in medicine to create treatments for diseases that have long stumped the scientific community. Obamas 2016 budget proposal grants $215 million to advance the field of precision medicine, an approach in which experts toss out their one-size-fits-all strategy to develop drugs or therapies that target the genetic makeup and lifestyle choices of each patient.

As part of the proposal, the Obama administration intends to give $130 million to the National Institutes of Health (NIH) to build a database of records that will include biological samples, test results, medical histories and genomic profiles of a million or more Americans. Theproject should present unprecedented opportunities for researchers but also a host of new challenges for an administration with a dicey record of data protection at HealthCare.gov and a history ofelectronic surveillance in the name of national security.

I think this is a bold initiative, says Michael Zimmer, an expert in Internet privacy issues at University of Wisconsin-Madison. What I'm hoping here is that, given the sensitivity of this data, they will engage with the right communities and do it in a transparent way.

Francis Collins, director of the NIH, has confirmed to International Business Times that many of the genomes included in the database will be gleaned from a network of 200 groups of scientists around the country who have enrolled, or are enrolling, at least 10,000 participants each for the studies. It should be possible to build the precision medicine initiative largely from existing studies, saving a great deal of time and money, he says.

Of course, amassing the data will only be half of the challenge; the federal government must also keep it safe. Holding a persons genomic and medical records is like having a window into their lifestyle, family history and possible future, and the risk is that such intimate information could be abused or misused if found in the wrong hands.

Some patient protections are already in place. The Common Rule, by which most federal agencies abide, prohibits research on human subjects without their consent except in special situations. The Privacy Rule of the Health Insurance Portability and Accountability Act also generally prohibits research on or the disclosure of information related to a patient's health without their consent among many universities and hospitals that may contribute to the nationwide study. And should this information ever leak out, Congress also passed the Genetic Information Nondiscrimination Act in 2008 to prevent insurers or employers from holding genetic findings against a person. Regardless, concerns still loom large in the minds of privacy advocates.

Pam Dixon, founder of a nonprofit concerned with privacy issues called the World Privacy Forum, argues that genomic data can be mishandled in ways that might impact an individuals family or children as well as themselves -- for instance, detecting an inheritable disease or predisposition for a late-onset illness. She thinks these concerns merit extra layers of protection. We cannot miss the mark on this one, she says.

The administration plans to grant $5 million to the Office of the National Coordinator for Health Information Technology for the sole purpose of ensuring data security. Zimmer takes this investment as a sign that the administration is making privacy a priority from the start.

Follow this link:

Obamas 'Precision Medicine' Database: How Safe And Private Is The Patient Data?

Sequencing genetic duplications could aid clinical interpretation

Copy number variations (deletions or duplications of large chunks of the genome) are a major cause of birth defects, intellectual disability, autism spectrum disorder and other developmental disorders. Still, geneticists can definitively say how a CNV, once discovered in someone's DNA, leads to one of these conditions in just a fraction of cases.

To aid in the interpretation of CNVs, researchers at Emory University School of Medicine have completed detailed maps of 184 duplications found in the genomes of individuals referred for genetic testing. The findings are scheduled for publication in the American Journal of Human Genetics.

"Ours is the first study to investigate a large cohort of clinically relevant duplications throughout the genome," says senior author Katie Rudd, PhD, assistant professor of human genetics at Emory University School of Medicine. "These new data could help geneticists explain CNV test results to referring doctors and parents, and also reveal mechanisms of how duplications form in the first place."

Despite advances in "next generation" DNA sequencing, the first step for patients who are referred to a clinical geneticist is currently a microarray. This is a scan using many probes across the genome, testing if someone's DNA has one, two, three or more copies of the DNA corresponding to the probe. (Two is the baseline.) From this scan, geneticists will have a ballpark estimate of where a deletion or duplication starts and ends, but won't know the breakpoints exactly.

"In a few years, advances in sequencing will make it possible to routinely capture data on copy number variation and breakpoints at the same time," Rudd says. "But for now, we have to do this extra step."

In addition, in comparison with deletions, duplications are more complicated. The extra DNA has to land somewhere, sometimes resulting in the disruption or warped regulation of nearby genes, which make it more difficult to pinpoint particular genes responsible for the individual's medical condition.

Most healthy people have a deletion or duplication of at least 100 kilobases in size. The individuals in the study were referred for clinical microarray testing with indications including intellectual disability, developmental delay, autism spectrum disorders, congenital anomalies, and dysmorphic features. Their CNVs were larger, with an average size of more than 500 kilobases. For reference, the entire haploid human genome, with about 19,000 genes, is about 3.3 million kilobases in size.

Rudd's team examined 184 duplications, and found that most are in tandem orientation and adjacent to the duplicated area. Most of the CNVs in the study were inherited from a parent. The researchers also found examples where a duplicated gene inserted into and disrupted another gene on a different chromosome.

In a few cases, a duplicated gene was fused together with another gene. This is a phenomenon often seen in cancer cells, where a DNA rearrangement leads to an abnormal activation of a growth- or survival-promoting gene. In these cases, the fusions were present in all cells in the body and not related to cancer, but could be responsible for the patient's condition.

"These fusion genes are intriguing but we don't know, just from looking at the DNA, if the gene is expressed," Rudd says. "These findings could be the starting point for follow-up investigation."

Read the original:

Sequencing genetic duplications could aid clinical interpretation

U.S. to analyze DNA from 1 million people

(MENAFN - Al-Anbaa) The United States has proposed analyzing genetic information from more than 1 million American volunteers as part of a new initiative to understand human disease and develop medicines targeted to an individual's genetic make-up. At the heart of the "precision medicine" initiative, announced on Friday by President Barack Obama, is the creation of a pool of people - healthy and ill, men and women, old and young - who would be studied to learn how genetic variants affect health and disease.

Officials hope genetic data from several hundred thousand participants in ongoing genetic studies would be used and other volunteers recruited to reach the 1 million total.

"Precision medicine gives us one of the greatest opportunities for new medical breakthroughs we've ever seen," Obama said, promising that it would "lay a foundation for a new era of life-saving discoveries."

The near-term goal is to create more and better treatments for cancer, Dr. Francis Collins, director of the National Institutes of Health (NIH), told reporters on a conference call on Thursday. Longer term, he said, the project would provide information on how to individualize treatment for a range of diseases.

The initial focus on cancer, he said, reflects the lethality of the disease and the significant advances against cancer that precision medicine has already made, though more work is needed.

The effort may raise alarm bells for privacy rights advocates who have questioned the government's ability to guarantee that DNA information is kept anonymous.

Obama promised that "privacy will be built in from day one."

View original post here:

U.S. to analyze DNA from 1 million people

Mayo genetic data bank could boost Obama’s new ‘precision …

WASHINGTON The Mayo Clinics cutting-edge pooling of patients genetic and medical data could soon become the model for an ambitious national databank envisioned by the Obama administration.

President Obama announced plans for the databank Friday as part of the $215 million precision medicine initiative that he will ask Congress to fund in the 2016 budget. The initiative includes gathering details from a million volunteers nationwide to help tailor genetic diagnoses and treatments of diseases.

If we have a big data set, a big pool of people thats varied, then that allows us to really map out not only the genome of one person, but now we can start seeing connections and patterns and correlations that helps us refine exactly what it is that were trying to do with respect to treatment, the president said at a White House ceremony, attended by Mayo Vice President Dr. Gianrico Farrugia.

Farrugia was invited to the White House because Mayo set up a successful biobank system at its Center for Individualized Medicine in 2009. The data repository reached its goal of assembling the genetic and medical details of 50,000 individuals for purposes of comparison with the idea that the knowledge would be distributed as widely as possible, said Farrugia.

Its transformational, he said. Anyone who uses the information [in the Mayo biobank] and generates new information [by doing so] is obligated to put that new information in the bank.

Farrugia said Mayo will await details of the new federal program and present them to a Mayo community advisory board and scientists in deciding whether to contribute to the national databank. But the aims of the administration appear to merge nicely with what Mayo has been doing for five years.

If we combine all these emerging technologies, if we focus them and make sure that the connections are made, then the possibility of discovering new cures, the possibility of applying medicines more efficiently and more effectively can improve individual health care, Obama said.

The White House had no direct conversations with Mayo as it prepared the precision medicine initiative, Farrugia said. However, the Rochester-based medical center did talk to several federal agencies.

Mayo has pioneered computerized analysis of shared data as a path to individual treatment. It recently entered into an agreement with health insurance giant UnitedHealth Group to create what is reportedly the largest health care database.

Now, Farrugia said, Mayo is committed to the presidents initiative, which also includes specific efforts to find gene-based cures for cancer.

See more here:

Mayo genetic data bank could boost Obama's new 'precision ...

What Is Personalized Medicine And Why Is Obama Supporting It With A $215 Million Pledge?

The Obama administration is proposing to create a large database of patient information, including genetic profiles and medical histories, to further research into precision medicine, which aims to create customized treatments based on a patients genetic makeup and lifestyle choices.

Precision, or personalized, medicine works much the same way that an eyeglass prescription or a blood transfusion is prescribed, based on a patient's exam results or blood type, and proponents believe this line of thinking may be extended to many more areas of medicine.

Jo Handelsman, associate director for science at the White House Office of Science and Technology, has called the $215 million budget allocation for the Precision Medicine Initiative in Obamas proposed 2016 budget a move away from the one-size-fits-all approach to medicine.

Obama's proposal grants $130 million to the National Institutes of Health to launch a national long-term study that will collect biological samples, genetic profiles and electronic health records from at least a million Americans.

Researchers may use an app to track the calorie consumption or environmental health impacts of participants through their smartphones and the database could include everything from their laboratory test results to MRI scans. Patient data will be anonymized and participation is strictly voluntary, the administration says. The system is meant to serve as a reservoir of information that researchers can tap while investigating the nuances of a particular disease in individual patients, or trying to identify genetic trends across treatment groups.

The administration, with its messy record of privacy violations committed in the name of national security, will also grant $5 million to the Office of the National Coordinator for Health Information Technology to build a data system that it says will protect the identities of patients whose information is included in the database. The National Institutes of Health will also host a forum in mid-February to discuss the challenges of creating a national research group to populate the database. Much of the patient information may be pulled from existing studies, according to scientists familiar with the project who spoke on background to Science magazine.

Obama gave researchers a glimpse into his zeal for precision medicine during the 2015 State of the Union address, but he clarified the details Friday.I want the country that eliminated polio and mapped the human genome to lead a new era of medicine -- one that delivers the right treatment at the right time, he said in his address.

The Cystic Fibrosis Foundation has long taken this approach to develop customized drugs for small groups of patients who share the same genetic mutation for the disease. The organization worked with Vertex Pharmaceuticals to create a drug called Kalydeco, which treats a mutation present in only4 percent of patients with cystic fibrosis according to a 2012 study in the American Journal of Respiratory and Critical Care Medicine. This focus on tailor-made medicine has nearly doubled the median life span of patients from 20 years to 40 years.

This research will dramatically advance our knowledge of diseases, how they originated and how we may prevent or treat them, Francis Collins, director of the National Institutes of Health, told the Washington Post.

Looking ahead, the administration is anxious to try to apply the same principles that have worked for cystic fibrosis to cancer. Obamas proposal requests $70 million for the National Cancer Institute to study the genetic underpinnings of several types of the disease, reports the New York Times.

Read more from the original source:

What Is Personalized Medicine And Why Is Obama Supporting It With A $215 Million Pledge?